10-Q: Tevogen Bio Reports Q3 Loss, Secures Funding Amid Nasdaq Warning

Tevogen Bio Holdings Inc. reported a net loss of $5.7 million for Q3 2025, while securing additional financing and facing a Nasdaq minimum bid price non-compliance notice.

Summary

• Tevogen Bio Holdings Inc. is a clinical-stage immunotherapy company focused on developing off-the-shelf T cell therapies for infectious diseases and cancers using its ExacTcell technology and Tevogen.AI initiative.
• The company reported a net loss of $5.7 million for the three months ended September 30, 2025, and $21.6 million for the nine months ended September 30, 2025.
• Cash on hand was $1.04 million as of September 30, 2025, down from $1.28 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $10.15 million.
• The company believes it has adequate cash and financial resources to operate for at least the next 12 months, combining current cash with $3.9 million from the Sales Agreement (post-Sep 30, 2025), amounts available under the Loan Agreement, and a $7.0 million committed grant from KRHP.
• A Phase 1 proof-of-concept trial for TVGN 489 (COVID-19 treatment) was completed, showing no dose-limiting toxicities or significant adverse events, rapid viral load reduction, and no progression of infection, reinfection, or Long COVID in patients during a six-month follow-up.
• The company does not plan to initiate a clinical trial until additional funding is received.
• Tevogen received a Nasdaq notification on September 23, 2025, for non-compliance with the $1.00 minimum bid price requirement and has 180 calendar days to regain compliance.
• Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.

Sentiment

Score: 3

Explanation: While the company has promising technology and a successful Phase 1 trial, significant financial challenges (increased losses, low cash, Nasdaq non-compliance, internal control weaknesses, and a default on notes payable) and a stated delay in clinical trials due to funding needs create a highly negative sentiment. The reliance on related-party financing, while providing some runway, also highlights the difficulty in securing broader market funding.

Positives

• Completed a successful Phase 1 proof-of-concept clinical trial for TVGN 489 for COVID-19, showing no dose-limiting toxicities or significant treatment-related adverse events, rapid viral load reduction, and no progression of infection, reinfection, or Long COVID during a six-month follow-up.
• Secured significant financing commitments, including $21.0 million remaining available under a $36.0 million Loan Agreement with The Patel Family, LLP, and a remaining $7.0 million committed grant from KRHP (affiliated with the Patel Family).
• Raised $3.1 million net proceeds from an at-the-market equity offering (Sales Agreement) between July 3, 2025, and September 30, 2025.
• The company's CEO, Ryan Saadi, made a capital contribution of $500,000 in June 2025.
• Possesses a robust intellectual property portfolio, including three U.S. patents for TVGN 489 and numerous pending applications for T cell therapies and AI-driven target identification.

Negatives

• Reported a net loss of $5.7 million for the three months ended September 30, 2025, and a significantly higher net loss of $21.6 million for the nine months ended September 30, 2025, compared to $4.3 million in the prior year period.
• Accumulated deficit increased to $135.0 million as of September 30, 2025, from $113.4 million at December 31, 2024.
• Cash balance decreased to $1.04 million as of September 30, 2025, from $1.28 million at December 31, 2024.
• Incurred $10.15 million in net cash used in operating activities for the nine months ended September 30, 2025.
• Received a Nasdaq notification on September 23, 2025, for non-compliance with the $1.00 minimum bid price requirement, risking delisting if compliance is not regained by March 23, 2026.
• Notes payable of $1.651 million, assumed during the Merger, are in default as of September 30, 2025.
• Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• The company does not plan to initiate a clinical trial until additional funding is received, indicating a dependency on future capital raises for pipeline advancement.

Risks

• Requires substantial additional financing to pursue business objectives and fund operations, which may not be available on acceptable terms or at all, potentially forcing delays or termination of product development and commercialization efforts.
• Failure to regain compliance with Nasdaq's $1.00 minimum closing bid price requirement or other listing criteria could lead to delisting, negatively affecting stock price and liquidity.
• The terms of Preferred Stock, Loan Agreement, and Sales Agreement may negatively impact the ability to raise additional capital through equity or debt financings due to potential substantial dilution or restrictive covenants.
• Uncertainties inherent in the execution, cost, and completion of pre-clinical studies and clinical trials, and risks related to regulatory review and approval and commercial development.
• Risks associated with intellectual property protection, including the ability to obtain and maintain patents and operate without infringing on others' rights.
• Increasing use of AI could lead to liability, violation of data security and privacy laws, or reputational damage.
• Computer systems may fail or suffer security breaches.
• Limited operating history makes it difficult to evaluate future prospects and risks.
• The company is subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development, with no guarantee of successful products or regulatory approval.

Future Outlook

The company anticipates incurring additional losses until it can generate significant sales from its product candidates. It plans to increase research and development expenses, personnel costs, and manufacturing infrastructure. Commercialization efforts, if product candidates receive marketing approval, will also lead to significantly increased expenses. The company does not plan to initiate a clinical trial until additional funding is received, highlighting a critical dependency on future capital raises for pipeline advancement. Future capital requirements are highly uncertain and depend on clinical trial progress, regulatory approvals, manufacturing scale-up, and market adoption.

Management Comments

• Management believes that cash of $1,037,094 as of September 30, 2025, and net proceeds through November 12, 2025, of $3.9 million pursuant to the Sales Agreement combined with the amounts available under the Loan Agreement and the remaining commitment for a $7,000,000 grant from KRHP will allow the Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these unaudited consolidated financial statements.
• The Company does not plan to initiate a clinical trial until additional funding is received.
• Management regularly evaluates different strategies to obtain funding for operations for subsequent periods, including private placements, licensing, partnerships, and public offerings.
• The Chief Executive Officer is the chief operating decision maker, using net loss to allocate resources and evaluate performance.

Industry Context

Tevogen Bio operates in the highly competitive and capital-intensive clinical-stage immunotherapy sector, specifically targeting T cell therapies for infectious diseases and cancers. Its focus on 'off-the-shelf' allogeneic therapies and integration of AI (Tevogen.AI) positions it within a cutting-edge segment of the biotech industry. The successful Phase 1 trial for TVGN 489 in COVID-19 is a positive signal, but the broader market for T-cell therapies, particularly in oncology, is dominated by larger players with significant R&D budgets and established pipelines. The company's ability to secure substantial related-party funding is crucial for its survival in an industry where long development cycles and high failure rates are common. The reliance on external funding for the next clinical trial is a common challenge for smaller biotech firms.

Comparison to Industry Standards

• The successful completion of a Phase 1 proof-of-concept trial for TVGN 489 without dose-limiting toxicities or significant adverse events is a positive indicator, aligning with early-stage clinical development goals for safety and preliminary efficacy. This is a standard achievement for advancing a drug candidate.
• The company's accumulated deficit of $135.0 million and ongoing net losses are typical for a clinical-stage biotechnology company that has not yet commercialized any products, similar to peers like Atara Biotherapeutics (ATRA) or Allogene Therapeutics (ALLO) in their early development phases, which also report significant R&D expenses and operating losses.
• The cash position of $1.04 million as of September 30, 2025, is very low for a biotech company, even with additional committed funding, and is below the typical cash runway seen in many publicly traded clinical-stage biotechs, which often aim for 18-24 months of liquidity. This indicates a more precarious financial position compared to industry benchmarks.
• The Nasdaq minimum bid price non-compliance is a significant concern, as delisting can severely impact liquidity and investor confidence, a challenge faced by many smaller, pre-revenue companies that struggle to maintain market capitalization and share price above regulatory thresholds.
• The reliance on related-party financing (Patel Family, KRHP) is common for early-stage companies but can raise questions about independent valuation and governance compared to broader institutional funding rounds seen in more mature biotech firms.

Corporate Governance

Legal Proceedings

• The company currently has no material legal proceedings pending.

Related Party Transactions

• Loan Agreement with The Patel Family, LLP (a related party) for an unsecured line of credit up to $36,000,000, with $4,400,000 drawn as of September 30, 2025, and $21,000,000 remaining available.
• Issued 1,000,000 shares of common stock to the Patel Family as an inducement/commitment fee for the Loan Agreement.
• The Patel Family holds purchase options for up to $14,000,000 of common stock and an additional amount up to the then-remaining undrawn term loan amount.
• Series A Preferred Stock ($2,000,000 proceeds), Series A-1 Preferred Stock ($3,000,000 deposit received, $3,000,000 remaining), and Series C Preferred Stock ($6,000,000 proceeds) were all purchased or are subject to purchase by the Patel Family.
• KRHP LLC, affiliated with the Patel Family, provided grants of $2,000,000 (January 2025) and $1,000,000 (August 2025), and committed an additional $7,000,000 in grant funding.
• Dr. Manmohan Patel of The Patel Family LLP was contracted in December 2024 to provide advisory services, receiving 6,000,000 RSUs.
• CD8 Technology Services LLC (CD8), associated with Dr. Patel, entered into a Master Services and Facilities Agreement with the company on April 17, 2025, for specialized manufacturing facilities and operational services.
• The CEO, Ryan Saadi, made a capital contribution of $500,000 in June 2025.
• Issued 40,000 Performance-Based RSUs to the wife of the CEO and 20,000 Performance-Based RSUs to Mehtaphoric Consulting Inc. (controlled by the CFO's daughter) in January 2023 for advisory and IT services, with compensation cost of $800,396 recognized upon achievement of performance condition.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity offerings (Sales Agreement) and potential conversion of preferred stock and warrants. The Nasdaq non-compliance poses a delisting risk, which would negatively impact liquidity and share price. The increased net loss and accumulated deficit erode shareholder equity.
• **Employees**: Stock-based compensation is a key element of compensation, but the company's financial challenges and need for further funding could create uncertainty regarding long-term stability and growth opportunities.
• **Creditors**: Notes payable of $1.651 million are in default, though the filing states no immediate transfer of shares or payments are required. This indicates a heightened credit risk.
• **Patients/Medical Community**: The successful Phase 1 trial for TVGN 489 is promising, but the delay in initiating further clinical trials due to funding constraints means potential therapies may not reach patients as quickly as hoped.
• **Regulatory Bodies**: The material weaknesses in internal control over financial reporting will require significant attention and remediation to ensure compliance with SEC requirements.

Next Steps

• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by March 23, 2026.
• Obtain additional funding to initiate further clinical trials for TVGN 489 and other product candidates.
• Continue to evaluate strategies for obtaining funding, including private placements, licensing, partnerships, and public offerings.
• Address material weaknesses in internal control over financial reporting.
• Advance pre-clinical studies and clinical trials for TVGN 489 and other product candidates.
• Scale up manufacturing processes and capabilities.
• Prepare regulatory filings for product candidates.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net losses, a critically low cash balance, and an accumulated deficit. The Nasdaq non-compliance notice for minimum bid price and the acknowledged material weaknesses in internal control over financial reporting are significant red flags, indicating operational and governance issues. While the Phase 1 trial results for TVGN 489 are positive, the explicit statement that no further clinical trials will commence without additional funding highlights a precarious future. The heavy reliance on related-party financing, while providing some short-term liquidity, does not alleviate the fundamental concerns about the company's ability to secure broader market capital and achieve commercial viability. The combination of worsening financial performance, regulatory non-compliance, and operational weaknesses suggests a high-risk investment with significant downside potential.

Keywords

Immunotherapy, T-cell therapy, Biotechnology, Clinical-stage, TVGN 489, COVID-19 treatment, ExacTcell, Tevogen.AI, Oncology, Infectious diseases, SEC filing, 10-Q, Nasdaq compliance, Capital raise, Financial results